Oncogene activation disturbs cellular processes and accommodates a complex landscape
of changes in the genome that contribute to genomic instability, which accelerates mutation …

Acute myeloid leukemia (AML) is a polyclonal and heterogeneous hematological
malignancy. Relapse and refractory after induction chemotherapy are still challenges for …

Most patients with acute myeloid leukemia (AML) relapse eventually because of the inability
to effectively eliminate leukemia stem cells (LSCs), prompting the search of new therapies to …

Leukemia stem cells (LSCs) are responsible for acute myeloid leukemia (AML)
chemotherapy resistance and relapse. Here, we discovered that miR-34c-5p, a microRNA …

Cells undergo senescence in response to various conditions, including telomere erosion,
oncogene activation and multiple cytokines. One of these cytokines, interleukin-6 (IL‑6), not …

Cellular senescence constitutes a permanent state of cell cycle arrest in proliferative cells
induced by different stresses. The exploration of tumor pathogenesis and therapies has …

Transformed cells have properties that allow them to survive and proliferate inappropriately.
These characteristics often arise as a result of mutations caused by DNA damage. p53 …

Activation of the MLL-ENL-ERtm oncogene initiates aberrant proliferation of myeloid
progenitors. Here, we show induction of a fail-safe mechanism mediated by the DNA …

Large regions of recurrent genomic loss are common in cancers; however, with a few well-
characterized exceptions, how they contribute to tumor pathogenesis remains largely …

Transcriptional regulators are recurrently altered through translocations, deletions, or
aberrant expression in acute myeloid leukemia (AML). Although critically important in …